Efficacy of the GMALL‐B‐ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non‐Hodgkin‐lymphomas with or without CNS involvement

Sakarou, M.; Eisele, Lewin; Hüttmann, Andreas

doi:10.1111/ejh.13199

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The survival rate in patients with mature B‐cell lymphoma was only 34% using long‐course chemotherapy suitable for lymphoblastic lymphoma 4 . Chemotherapy with risk‐stratification, short duration, and pulse treatment based on biological behavior has been associated with favorable outcomes 12,13 . The 5‐year overall survival rate of the 25 pediatric patients in our study was 85.8% ± 5.0%.…”

Section: Discussionmentioning

confidence: 67%

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children

Zhu

Zhen

Wang

et al. 2021

Pediatric Investigation

View full text Add to dashboard Cite

ImportanceBurkitt lymphoma with bone marrow involvement and Burkitt leukemia behave aggressively. Thus far, there are limited data concerning survival and toxicity in Chinese children with Burkitt lymphoma or Burkitt leukemia who have undergone treatment with the non‐Hodgkin’s lymphoma Berlin‐Frankfurt‐Münster‐90/95 (NHL‐BFM‐90/95) protocol.ObjectiveTo analyze outcomes and toxicity in pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia following treatment with the NHL‐BFM‐90/95 protocol.MethodsPatients aged <18 years with bone marrow involvement/leukemia who were treated with the NHL‐BFM‐90/95 protocol, with or without rituximab, in Sun Yat‐Sen University Cancer Center from April 2004 to December 2018 were included in this retrospective analysis.ResultsTwenty‐five patients were eligible. Burkitt lymphoma with bone marrow involvement and Burkitt leukemia were present in 10 and 15 patients, respectively. Central nervous system infiltration was not observed in any patients. All patients underwent chemotherapy involving NHL‐BFM‐90/95 protocol. Six courses of treatment were administered to each patient (v‐AA‐BB‐CC‐AA‐BB‐CC). The BFM‐90/95 plus rituximab protocol was administered to 13 patients. The median follow‐up interval was 31.9 months (range, 2.5–158 months). Of the 25 patients, four died: three died of tumor progression and one died of therapy abandonment after relief of tumor lysis syndrome. The estimated 5‐year event‐free survival and overall survival rates were both 85.8% ± 5.0%.InterpretationChinese pediatric patients who exhibit Burkitt lymphoma with bone marrow involvement or Burkitt leukemia can achieve optimal treatment outcomes and exhibit good tolerance when using the NHL‐BFM‐90/95 protocol.

show abstract

Section: Discussionmentioning

confidence: 67%

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children

Zhu

Zhen

Wang

et al. 2021

Pediatric Investigation

View full text Add to dashboard Cite

show abstract

“…ENKTL is an uncommon subtype of NHL, with a survival rate of 5 years ranging from 45.3% to 68.9% [6,16,17]. The frequency of NHL involving the CNS was 4% among all CNS malignant diseases, and the most common subtype of NHL involving the CNS was diffuse large B cell lymphoma (DLBCL) [18,19]. ENKTL involving the CNS is extremely rare, and has been reported in only a few studies.…”

Section: Discussionmentioning

confidence: 99%

Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series

Ren²,

Li³

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

Purpose patients with central nervous system (CNS) involvement at initial diagnosis of Extranodal NK-T-cell lymphoma (ENKTL) are exceedingly rare, and the clinicopathologic features of CNS involvement have not been well characterized.Methods We reviewed 662 patients with ENKTL from August 2008 to September 2019. Their clinical and pathological features, treatments, and survival outcomes were analyzed.Results The median follow-up time was 72 months. Nine of 662 (1.4%) patients were diagnosed with CNS involvement. Among them, the median age was 37 years, and seven patients were male. All patients had positive EBV-DNA, and three patients were asymptomatic at the time of diagnosis with CNS involvement. Common extranodal involved sites included bone, paranasal sinuses, breast, kidney, adrenal gland and bone marrow. All patients were positive for cytoplasmic CD3ε, cytotoxic granule proteins, and EBER and negative for CD20. All patients received intrathecal chemotherapy and at least one cycle of systemic chemotherapy. Seven patients had died and two were still alive by the last follow-up. The median overall survival (OS) in patients with CNS involvement at initial diagnosis of ENKTL was 9 months, and the 1-year OS was 44.4%. Five patients achieved a complete response after asparaginase-based chemotherapy; two were still alive, one died of systemic progression, one died of ENKTL-associated hemophagocytic syndrome, and one died of treatment-related infections.Conclusion CNS involvement at initial diagnosis of ENKTL is extremely rare with poor prognosis. There is no standard treatment, and asparaginase-based chemotherapy combined with intrathecal chemotherapy might yield good e cacy.

show abstract

“…Depending on available resources, clinical factors and patient preference, primary mediastinal B-cell lymphoma (PMBL) could be preferably treated either with DA-EPOCH-R alone [44] or with combined modalities of R-CHOP-21 followed by radiation. In Burkitt lymphoma (BL), well-known intensive regimens achieved a similar efficacy, but an outpatient regimen such as GMALL 2002 could be a preferable choice within the context of the pandemic [45]. Autologous HSCT consolidation in first line treatment for T-cell lymphoma is not supported by prospective controlled trials, thus the risk/benefit should be clearly explained to patients especially for those achieving a complete response.…”

Section: Aggressive Lymphomasmentioning

confidence: 99%

Evolving management strategies for lymphomas during the COVID-19 pandemic

Lang

Kuruvilla

2020

Leukemia & Lymphoma

View full text Add to dashboard Cite

The evolving CoViD-19 pandemic has raised unprecedented challenges for physicians who face significant constraints in medical resources and cancer therapies. The management of patients with lymphoma represents a unique challenge given the heterogeneity of the patient population and treatment goals as well as the myriad choices of therapy available to clinicians. Adaptation in clinical practice with the goal of maintaining appropriate continuity and quality of care while mitigating exposure risk has forced clinicians around the world to develop new standards of practice and can pose difficult ethical choices in vulnerable patient populations. Based on recommendations formulated by several medical groups and societies, this article provides an overview of the general and specific practical considerations that apply to the care of lymphoma patients during the outbreak. We hope to provide a practical framework to help guide physicians in their therapeutic choices and facilitate the ongoing management of this specific patient population.

show abstract

Efficacy of the GMALL‐B‐ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non‐Hodgkin‐lymphomas with or without CNS involvement

Cited by 5 publications

References 22 publications

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children

Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series

Evolving management strategies for lymphomas during the COVID-19 pandemic

Contact Info

Product

Resources

About